IMMUNOPRECISE ANTIBODIES LTD. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,616,293 common shares of the Company, at a price to the public of $13.45 per Common Share, less underwriting discounts and commissions, for gross proceeds to the Company of approximately $21.7 million.
February 3, 2021
· 6 min read